ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR was delisted on the 27th of May, 2025.
22 hedge funds and large institutions have $8.55M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2019 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 4 closing their positions.
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
10% more funds holding
Funds holding: 20 → 22 (+2)
2.66% more ownership
Funds ownership: 23.44% → 26.1% (+2.7%)
4% less capital invested
Capital invested by funds: $8.89M → $8.55M (-$340K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$635K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$601K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$113K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$69.2K |
| 5 |
BL
BCWM LLC
Overland Park,
Kansas
|
+$69K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SG
StoneX Group
New York
|
-$350K |
| 2 |
Jane Street
New York
|
-$348K |
| 3 |
SWM
SeaCrest Wealth Management
Purchase,
New York
|
-$71.7K |
| 4 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$21K |
| 5 |
RFWA
RPg Family Wealth Advisory
Burlington,
Massachusetts
|
-$17.9K |
CNCR Hedge Fund Activity: Q3 2019 in Review
22 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) for Q3 2019, worth a combined $8.55M — down 3.8% from $8.89M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new CNCR positions and 4 closed out — a net gain of 2 holders — while 6 added to existing stakes and 5 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $635K. The largest seller was StoneX Group, exiting entirely with an estimated $350K sold.
- 22 institutional investors held ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) as of Q3 2019, up from 20 in Q2 2019.
- Funds reported $8.55M of ETF Series Solutions Trust Range Cancer Therapeutics ETF stock for Q3 2019, down 3.8% quarter-over-quarter.
- 6 funds opened new ETF Series Solutions Trust Range Cancer Therapeutics ETF positions in Q3 2019 and 4 closed out, a net change of +2 holders.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF buyer in Q3 2019 was Morgan Stanley, an estimated $635K added.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF seller in Q3 2019 was StoneX Group, an estimated $350K sold.
Based on aggregated 13F filings for Q3 2019.